Denosumab, a fully human monoclonal antibody to RANKL, inhibits bone resorption and increases BMD in knock-in mice that express chimeric (murine/human) RANKL - Kostenuik, PJ; Nguyen, HQ; McCabe, J (J Bone Miner Res, 2009)
et al.